​

Protagonist Therapeutics (PTGX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

PTGX Stock Forecast

Protagonist Therapeutics (PTGX) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $73.00, with a high of $76.00 and a low of $70.00. This represents a 29.62% increase from the last price of $56.32.

$20 $32 $44 $56 $68 $80 High: $76 Avg: $73 Low: $70 Last Closed Price: $56.32

PTGX Stock Rating

Protagonist Therapeutics stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (95.00%), 1 Hold (5.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 1 19 Strong Sell Sell Hold Buy Strong Buy

PTGX Price Target Upside V Benchmarks

TypeNameUpside
StockProtagonist Therapeutics29.62%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts--7
Avg Price Target--$61.29
Last Closing Price$56.32$56.32$56.32
Upside/Downside--8.82%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25451--10
May, 25451--10
Apr, 25451--10
Mar, 25451--10
Feb, 25451--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 11, 2025Wedbush$70.00$59.7617.14%24.29%
Mar 03, 2025BTIG$73.00$38.5089.61%29.62%
Dec 05, 2024Etzer DaroutBMO Capital$62.00$41.6848.75%10.09%
Nov 22, 2024Srikripa DevarakondaTruist Financial$60.00$46.4629.14%6.53%
Sep 12, 2024Douglas TsaoH.C. Wainwright$50.00$45.0810.91%-11.22%
Jun 17, 2024Douglas TsaoH.C. Wainwright$38.00$32.8615.64%-32.53%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 11, 2025WedbushOutperformOutperformhold
Mar 11, 2025BMO CapitalOutperformOutperformhold
Mar 11, 2025H.C. WainwrightBuyBuyhold
Dec 05, 2024BMO CapitalOutperforminitialise
Oct 14, 2024Cowen & Co.BuyBuyhold
Sep 24, 2024Cowen & Co.Buyinitialise
Sep 12, 2024H.C. WainwrightBuyBuyhold
Aug 07, 2024H.C. WainwrightBuyBuyhold
Jul 24, 2024BTIGBuyBuyhold
Jun 17, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-3 $-1 $1 $3 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.92$-2.65$-2.52$-1.39$4.47----
Avg Forecast$-1.94$-2.71$-2.57$-1.62$2.37$-1.30$-1.16$-1.40$0.48
High Forecast$-1.37$-1.92$-1.61$-1.16$3.24$-0.15$1.99$0.71$0.99
Low Forecast$-3.24$-4.54$-4.10$-2.09$1.71$-2.27$-2.71$-3.11$0.06
Surprise %-1.03%-2.21%-1.95%-14.20%88.61%----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$28.63M$27.36M$26.58M$60.00M-----
Avg Forecast$25.69M$23.20M$29.85M$60.00M$313.30M$97.97M$135.83M$123.87M$262.81M
High Forecast$39.01M$35.22M$43.48M$108.70M$376.48M$177.49M$139.83M$224.40M$476.11M
Low Forecast$19.93M$17.99M$21.25M$19.90M$266.93M$32.50M$131.82M$41.09M$87.17M
Surprise %11.43%17.93%-10.95%------

Net Income Forecast

$-200M $-100M $0 $100M $200M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-66.15M$-122.63M$-123.41M$-78.95M$275.19M----
Avg Forecast$-109.89M$-122.29M$-137.72M$-78.95M$170.85M$-89.38M$-74.54M$-69.47M$27.36M
High Forecast$-77.83M$-97.83M$-110.18M$-63.16M$183.88M$-8.53M$112.84M$40.54M$56.23M
Low Forecast$-183.94M$-146.75M$-165.27M$-94.75M$97.25M$-128.95M$-153.72M$-176.41M$3.59M
Surprise %-39.81%0.27%-10.39%-61.07%----

PTGX Forecast FAQ

Is Protagonist Therapeutics stock a buy?

Protagonist Therapeutics stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Protagonist Therapeutics is a favorable investment for most analysts.

What is Protagonist Therapeutics's price target?

Protagonist Therapeutics's price target, set by 20 Wall Street analysts, averages $73 over the next 12 months. The price target range spans from $70 at the low end to $76 at the high end, suggesting a potential 29.62% change from the previous closing price of $56.32.

How does Protagonist Therapeutics stock forecast compare to its benchmarks?

Protagonist Therapeutics's stock forecast shows a 29.62% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Protagonist Therapeutics over the past three months?

  • June 2025: 40.00% Strong Buy, 50.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 40.00% Strong Buy, 50.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 40.00% Strong Buy, 50.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Protagonist Therapeutics’s EPS forecast?

Protagonist Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.3, marking a -129.08% decrease from the reported $4.47 in 2024. Estimates for the following years are $-1.16 in 2026, $-1.4 in 2027, and $0.48 in 2028.

What is Protagonist Therapeutics’s revenue forecast?

Protagonist Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $97.97M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $135.83M, followed by $123.87M for 2027, and $262.81M for 2028.

What is Protagonist Therapeutics’s net income forecast?

Protagonist Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-89.382M, representing a -132.48% decrease from the reported $275.19M in 2024. Projections indicate $-74.543M in 2026, $-69.472M in 2027, and $27.36M in 2028.